Skip to main content
SleepCited
Figure 1
Figure 1.

Inflammation-associated biochemical pathways. Inflammatory signaling, most importantly interferon gamma (IFN-γ), stimulates neopterin synthesis via GTP cyclohydrolase 1 (GTP-CH-I) and tryptophan (Trp) catabolism along the kynurenine (Kyn) axis. Neopterin formation occurs mainly in human macrophages (MΦ) and dendritic cells (DC) at the expense of tetrahydrobiopterin (BH4). BH4 is a cofactor of monoxygenases, e.g., phenylalanine 4-monooxygenase (PAH), tyrosine 3-monooxygenase (TH), tryptophan 5-monooxygenases (TPH), and nitric oxide synthases (NOS). BH4 can be synthetized by other cell types, but it is oxidation labile and may diminish in situations of oxidative stress. Abbreviations: KynA = kynurenic acid, indoleamine 2,3-dioxygenase 1 (IDO-1), NAD = nicotinamide adenine dinucleotide, Phe = phenylalanine, QuinA = quinolinic acid, Tyr = tyrosine. Metabolites analyzed in the study are in bold and highlighted grey. Dashed arrows indicate biosynthetic processes in which more than one step/enzyme is involved. Figure licensed by Talia Piater.

Description

Study design or participant characteristics for the investigation of persistent symptoms and IFN-gamma-mediated metabolic pathways following COVID-19 infection.

Figure 1

Diagram

Source Paper

Persistent Symptoms and IFN-γ-Mediated Pathways after COVID-19.

Journal of personalized medicine (2023)

PMID: 37511668

DOI: 10.3390/jpm13071055

Cite This Figure

![Figure 1: Study design or participant characteristics for the investigation of persistent symptoms and IFN-gamma-mediated metabolic pathways following COVID-19 infection.](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10382041/bin/jpm-13-01055-g001.jpg)

> Source: Talia Piater et al. "Persistent Symptoms and IFN-γ-Mediated Pathways after COVID-19.." *Journal of personalized medicine*, 2023. PMID: [37511668](https://pubmed.ncbi.nlm.nih.gov/37511668/)
<figure>
  <img src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10382041/bin/jpm-13-01055-g001.jpg" alt="Study design or participant characteristics for the investigation of persistent symptoms and IFN-gamma-mediated metabolic pathways following COVID-19 infection." />
  <figcaption>Figure 1. Study design or participant characteristics for the investigation of persistent symptoms and IFN-gamma-mediated metabolic pathways following COVID-19 infection.<br>  Source: Talia Piater et al. "Persistent Symptoms and IFN-γ-Mediated Pathways after COVID-19.." <em>Journal of personalized medicine</em>, 2023. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37511668/">37511668</a></figcaption>
</figure>